Wall Street Analyst Initiated Abbott Laboratories [ABT]. What else is Wall St. saying


Abbott Laboratories [NYSE: ABT] slipped around -0.99 points on Tuesday, while shares priced at $140.47 at the close of the session, down -0.70%. The company report on December 21, 2021 that Abbott to Present at J.P. Morgan Healthcare Conference.

Abbott (NYSE: ABT) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, 2022. Robert B. Ford, chairman and chief executive officer, will present at 8 a.m. Central time.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


A live webcast of the presentation will be accessible through Abbott’s Investor Relations website at www.abbottinvestor.com. An archived edition of the presentation will be available later that day.

Abbott Laboratories stock is now 28.29% up from its year-to-date (YTD) trading value. ABT Stock saw the intraday high of $141.71 and lowest of $140.13 per share. The company’s 52-week high price is 142.60, which means current price is +33.32% above from all time high which was touched on 12/27/21.

Compared to the average trading volume of 5.44M shares, ABT reached a trading volume of 3292045 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Abbott Laboratories [ABT]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $142.68 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 10, 2021. The new note on the price target was released on October 27, 2021, representing the official price target for Abbott Laboratories stock.

The Average True Range (ATR) for Abbott Laboratories is set at 2.74, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 5.86. The Price to Book ratio for the last quarter was 7.24, with the Price to Cash per share for the same quarter was set at 5.49. Price to Free Cash Flow for ABT in the course of the last twelve months was 39.57 with Quick ratio for the last quarter at 1.40.

How has ABT stock performed recently?

Abbott Laboratories [ABT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.07. With this latest performance, ABT shares gained by 11.59% in over the last four-week period, additionally plugging by 19.84% over the last 6 months – not to mention a rise of 30.32% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 68.45, with the RSI for the last a single of trading hit 70.39, and the three-weeks RSI is set at 66.45 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 129.63, while it was recorded at 139.07 for the last single week of trading, and 122.06 for the last 200 days.

Abbott Laboratories [ABT]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +15.29 and a Gross Margin at +50.21. Abbott Laboratories’s Net Margin is presently recorded at +12.86.

Return on Total Capital for ABT is now 10.24, given the latest momentum, and Return on Invested Capital for the company is 8.83. Return on Equity for this stock inclined to 13.93, with Return on Assets sitting at 6.34. When it comes to the capital structure of this company, Abbott Laboratories [ABT] has a Total Debt to Total Equity ratio set at 60.67. Additionally, ABT Total Debt to Total Capital is recorded at 37.76, with Total Debt to Total Assets ending up at 27.42. Long-Term Debt to Equity for the company is recorded at 59.26, with the Long-Term Debt to Total Capital now at 36.89.

Reflecting on the efficiency of the workforce at the company, Abbott Laboratories [ABT] managed to generate an average of $40,817 per employee. Receivables Turnover for the company is 5.85 with a Total Asset Turnover recorded at a value of 0.49.Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.80.

Earnings analysis for Abbott Laboratories [ABT]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 13.12%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Insider trade positions for Abbott Laboratories [ABT]

There are presently around $185,772 million, or 75.50% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 148,779,946, which is approximately 0.633% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 134,318,636 shares of the stock with an approximate value of $19.0 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $11.95 billion in ABT stock with ownership of nearly -1.594% of the company’s market capitalization.

Positions in Abbott Laboratories stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,141 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 40,963,700 shares. Additionally, 1,066 investors decreased positions by around 40,713,278 shares, while 411 investors held positions by with 1,231,571,007 shares. The mentioned changes placed institutional holdings at 1,313,247,985 shares, according to the latest SEC report filing. ABT stock had 139 new institutional investments in for a total of 6,091,820 shares, while 84 institutional investors sold positions of 2,119,601 shares during the same period.